Diabetic macular edema (DME) is a common cause of visual impairment in diabetic patients.
It is caused by an increase in the permeability of the perifoveal capillaries and a disruption of …

Purpose: To evaluate the efficacy of intravitreal injections of two different dosages of
bevacizumab (Avastin) for treating diffuse diabetic macular edema. Methods: Fifty-two eyes …

Purpose: To evaluate anatomic and visual acuity (VA) results of pars plana vitrectomy (PPV)
with internal limiting membrane (ILM) peeling for diffuse diabetic macular edema (DME), and …

Aim: To compare the effects of intravitreal bevacizumab on different morphologic patterns of
diabetic macular edema (DME) classified using optical coherence tomography (OCT) …

visual loss associated with uveitis (Rothova et al. 1996). Intravitreal triamcinolone (IVTA) has
been used successfully as a primary treatment, particularly in unilateral disease, but a single …

Purpose: To determine safety and efficacy of intravitreal triamcinolone acetonide (IVTA) for
refractory clinically significant diabetic macular edema (DME). Design: Prospective …

Diabetic macular edema is an important cause of visual loss in the developed world and
may frequently lead to irreversible changes in visual acuity. The Early Treatment Diabetic …

Purpose: Intravitreal bevacizumab (Avastin®) induces a transient improvement in diabetic
macular edema, necessitating repeated injections. Here, we report the results of repeated …

Purpose To compare the short-term effects of intravitreal triamcinolone acetonide (IVTA) with
those of intravitreal bevacizumab (IVB) injection for diabetic macular edema (DME). Methods …

Purpose: To compare the efficacy of intravitreal injection of triamcinolone acetonide (IVTA)
for diabetic macular edema (DME) in vitrectomized eyes with DME without vitrectomy eyes …